JP7093764B2 - 骨髄異形成症候群の治療方法 - Google Patents

骨髄異形成症候群の治療方法 Download PDF

Info

Publication number
JP7093764B2
JP7093764B2 JP2019505515A JP2019505515A JP7093764B2 JP 7093764 B2 JP7093764 B2 JP 7093764B2 JP 2019505515 A JP2019505515 A JP 2019505515A JP 2019505515 A JP2019505515 A JP 2019505515A JP 7093764 B2 JP7093764 B2 JP 7093764B2
Authority
JP
Japan
Prior art keywords
myelodysplastic syndrome
certain embodiments
compound
weight
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019505515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528260A5 (enExample
JP2019528260A (ja
Inventor
アマタンゲロ マイケル
フ シャオラン
サクルタ アンジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority claimed from PCT/US2017/045055 external-priority patent/WO2018026894A1/en
Publication of JP2019528260A publication Critical patent/JP2019528260A/ja
Publication of JP2019528260A5 publication Critical patent/JP2019528260A5/ja
Application granted granted Critical
Publication of JP7093764B2 publication Critical patent/JP7093764B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019505515A 2016-08-03 2017-08-02 骨髄異形成症候群の治療方法 Active JP7093764B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662370373P 2016-08-03 2016-08-03
US62/370,373 2016-08-03
US201662429649P 2016-12-02 2016-12-02
US62/429,649 2016-12-02
PCT/US2017/045055 WO2018026894A1 (en) 2016-08-03 2017-08-02 Methods of treatment of myelodysplastic syndrome

Publications (3)

Publication Number Publication Date
JP2019528260A JP2019528260A (ja) 2019-10-10
JP2019528260A5 JP2019528260A5 (enExample) 2020-09-17
JP7093764B2 true JP7093764B2 (ja) 2022-06-30

Family

ID=68169055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019505515A Active JP7093764B2 (ja) 2016-08-03 2017-08-02 骨髄異形成症候群の治療方法

Country Status (1)

Country Link
JP (1) JP7093764B2 (enExample)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518069A (ja) 2011-06-17 2014-07-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 骨髄異形成症候群対象の生存率を予測するための変異シグネチャー
WO2014183122A1 (en) 2013-05-10 2014-11-13 The Broad Institute, Inc. Methods for determining response to a hypomethylating agent
WO2015017821A2 (en) 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016090273A1 (en) 2014-12-05 2016-06-09 Foundation Medicine, Inc. Multigene analysis of tumor samples
JP2018504429A (ja) 2015-02-04 2018-02-15 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518069A (ja) 2011-06-17 2014-07-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 骨髄異形成症候群対象の生存率を予測するための変異シグネチャー
WO2014183122A1 (en) 2013-05-10 2014-11-13 The Broad Institute, Inc. Methods for determining response to a hypomethylating agent
WO2015017821A2 (en) 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016090273A1 (en) 2014-12-05 2016-06-09 Foundation Medicine, Inc. Multigene analysis of tumor samples
JP2018504429A (ja) 2015-02-04 2018-02-15 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法

Also Published As

Publication number Publication date
JP2019528260A (ja) 2019-10-10

Similar Documents

Publication Publication Date Title
JP6930991B2 (ja) 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤
JP6852073B2 (ja) 悪性病変を処置する方法
JP6895956B2 (ja) 悪性腫瘍を治療するための併用療法
EP3493809B1 (en) Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) 骨髄異形成症候群の治療方法
HK40002835A (en) Ivosidenib for use in the treatment of relapsed/refractory aml
HK40002835B (en) Ivosidenib for use in the treatment of relapsed/refractory aml

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220620

R150 Certificate of patent or registration of utility model

Ref document number: 7093764

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250